Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Rapid Micro Biosystems (RPID) over the last 6 years, with Q3 2025 value amounting to -$618000.0.

  • Rapid Micro Biosystems' Change in Receivables rose 5137.69% to -$618000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 111197.6%. This contributed to the annual value of $2.0 million for FY2024, which is 111901.84% up from last year.
  • Rapid Micro Biosystems' Change in Receivables amounted to -$618000.0 in Q3 2025, which was up 5137.69% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Rapid Micro Biosystems' Change in Receivables ranged from a high of $3.8 million in Q4 2024 and a low of -$3.0 million during Q1 2025
  • For the 5-year period, Rapid Micro Biosystems' Change in Receivables averaged around $23263.2, with its median value being $90000.0 (2024).
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 7110000.0% in 2022, then plummeted by 87840.91% in 2023.
  • Over the past 5 years, Rapid Micro Biosystems' Change in Receivables (Quarter) stood at -$1000.0 in 2021, then surged by 71100.0% to $710000.0 in 2022, then skyrocketed by 128.87% to $1.6 million in 2023, then skyrocketed by 132.55% to $3.8 million in 2024, then tumbled by 116.35% to -$618000.0 in 2025.
  • Its Change in Receivables stands at -$618000.0 for Q3 2025, versus $1.5 million for Q2 2025 and -$3.0 million for Q1 2025.